3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
6
Pancreatic Neoplasms
5
Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Basal Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Liver Cirrhosis
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Gemcitabine
33
Cisplatin
22
pembrolizumab
21
Magnetic Resonance Spectroscopy
18
Specimen Handling
16
durvalumab
12
Mitomycin
10
enfortumab vedotin
9
avelumab
9
Nivolumab
9
Cystoscopy
9
Fluorouracil
8
Carboplatin
8
Radiation
7
Cystectomy
7
Radiotherapy
6
Immunoglobulin G
6
Docetaxel
6
Disulfides
6
atezolizumab
5
Transurethral Resection of Bladder
5
Mitozytrex
5
Biopsy
5
tremelimumab
4
sacituzumab govitecan
4
erdafitinib
4
dehydroftorafur
4
Standard of Care
4
Platinum
4
1,2-diaminocyclohexaneplatinum II citrate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Erlotinib Hydrochloride
×
90 days
×
Clear all
No trials found.